175 related articles for article (PubMed ID: 18241321)
1. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
4. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
5. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
6. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
Lapham S; Forman R; Alexander M; Illeperuma A; Bohn MJ
J Subst Abuse Treat; 2009 Jan; 36(1):1-6. PubMed ID: 18775624
[TBL] [Abstract][Full Text] [Related]
7. Extended-release naltrexone for treatment of alcohol dependence in primary care.
Lee JD; Grossman E; DiRocco D; Truncali A; Hanley K; Stevens D; Rotrosen J; Gourevitch MN
J Subst Abuse Treat; 2010 Jul; 39(1):14-21. PubMed ID: 20363090
[TBL] [Abstract][Full Text] [Related]
8. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Lapham SC; McMillan GP
J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
[TBL] [Abstract][Full Text] [Related]
9. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Pettinati HM; Gastfriend DR; Dong Q; Kranzler HR; O'Malley SS
Alcohol Clin Exp Res; 2009 Feb; 33(2):350-6. PubMed ID: 19053979
[TBL] [Abstract][Full Text] [Related]
10. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Vagenas P; Di Paola A; Herme M; Lincoln T; Skiest DJ; Altice FL; Springer SA
J Subst Abuse Treat; 2014 Jul; 47(1):35-40. PubMed ID: 24674234
[TBL] [Abstract][Full Text] [Related]
12. Early treatment response in alcohol dependence with extended-release naltrexone.
Ciraulo DA; Dong Q; Silverman BL; Gastfriend DR; Pettinati HM
J Clin Psychiatry; 2008 Feb; 69(2):190-5. PubMed ID: 18348601
[TBL] [Abstract][Full Text] [Related]
13. Long-acting injectable naltrexone for the treatment of alcohol dependence.
Mannelli P; Peindl K; Masand PS; Patkar AA
Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
[TBL] [Abstract][Full Text] [Related]
14. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
Mitchell MC; Memisoglu A; Silverman BL
J Stud Alcohol Drugs; 2012 Nov; 73(6):991-7. PubMed ID: 23036218
[TBL] [Abstract][Full Text] [Related]
15. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
17. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.
Lukas SE; Lowen SB; Lindsey KP; Conn N; Tartarini W; Rodolico J; Mallya G; Palmer C; Penetar DM
Neuroimage; 2013 Sep; 78():176-85. PubMed ID: 23571420
[TBL] [Abstract][Full Text] [Related]
18. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
Lee JD; Grossman E; Huben L; Manseau M; McNeely J; Rotrosen J; Stevens D; Gourevitch MN
J Subst Abuse Treat; 2012 Dec; 43(4):458-62. PubMed ID: 22985676
[TBL] [Abstract][Full Text] [Related]
19. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
20. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
Finigan MW; Perkins T; Zold-Kilbourn P; Parks J; Stringer M
J Subst Abuse Treat; 2011 Oct; 41(3):288-93. PubMed ID: 21696912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
